ABEONA THERAPEUTICS INC. (ABEO) Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Abeona Therapeutics Inc. NASDAQ:ABEO Healthcare · Biotechnology
Mkt Cap $248.75M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics granted restricted stock inducement awards covering up to 7,200 shares to two newly hired non-executive employees under Nasdaq Listing Rule 5635(c)(4).
The awards were approved by the Compensation Committee on September 30, 2026, and vest one-third annually over three years subject to continued employment.
The grant size is immaterial relative to a commercial-stage biopharma; this is boilerplate HR disclosure, not a strategic or financial update.
• 0mo ago AI analysis › Press Release ● Major
Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)
globenewswire.com • 1mo ago Press Release
Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
Abeona Therapeutics activated University of Florida Health in Gainesville as the eighth Qualified Treatment Center for ZEVASKYN, its approved autologous gene-modified cellular sheet therapy for wounds in recessive dystrophic epidermolysis bullosa.
UF Health is now the sole ZEVASKYN treatment center across the Southeastern United States and has already begun patient identification and onboarding activities.
The activation modestly widens ZEVASKYN's commercial footprint and access funnel, though the release disclosed no patient volumes, revenue, or utilization figures.
• 1mo ago AI analysis › Press Release
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
Abeona Therapeutics management will participate in three investor conferences in September 2026: a fireside chat at the Cantor Global Healthcare Conference on September 9, a company presentation at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, and a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 16.
Live webcasts of the fireside chats and company presentation will be available on the Investors section of Abeona's website, with replays accessible for a limited time.
Abeona is a commercial-stage biopharmaceutical company whose ZEVASKYN gene therapy for recessive dystrophic epidermolysis bullosa is on the market, with a pipeline led by ABO-701, an engineered T-cell therapy targeting PSMA in solid tumors.
• 1mo ago AI analysis › Press Release
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona granted an aggregate of 13,300 restricted shares to five new non-executive employees as a hiring inducement under Nasdaq Rule 5635(c)(4).
The awards, approved by the Compensation Committee on August 31, 2026, vest in equal annual installments over three years subject to continued employment.
This filing is a routine administrative disclosure related to employee compensation.
• 2mo ago AI analysis › Press Release ● Major ⚠ 2
Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update
Abeona reported Q2 revenue of $11.4 million, a 31% increase from the prior quarter, driven by the treatment of five patients with ZEVASKYN.
Commercial execution advanced with the activation of new Qualified Treatment Centers and the securing of CMS NTAP status to facilitate Medicare reimbursement starting October 1.
The company ended the quarter with $146.8 million in cash and short-term investments, down from $191.4 million at year-end, while R&D expenses decreased significantly to $5.0 million.
• 2mo ago AI analysis › Press Release
Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
Abeona Therapeutics announced it will host a conference call on August 13, 2026, to discuss its financial results for the second quarter of 2026.
The company stated that its full financial results for the period will be released in a press release prior to the start of the call.
A live webcast and archived replay will be available on the Investors & Media section of the company’s website for 30 days following the event.
• 2mo ago AI analysis › Press Release ● Major
CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®
Abeona Therapeutics announced that CMS granted New Technology Add-On Payment status for ZEVASKYN under the FY 2027 Hospital IPPS Final Rule.
This designation provides supplemental Medicare reimbursement above standard payments, supporting access and optimizing treatment center economics for the gene therapy.
ZEVASKYN is the first and only autologous cell sheet-based gene therapy approved for wounds in patients with recessive dystrophic epidermolysis bullosa.
• 2mo ago AI analysis › Press Release
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics granted restricted stock awards totaling 10,800 shares to two new non-executive employees as an employment inducement.
The awards were approved by the Compensation Committee on July 31, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4), with vesting scheduled over three years.
Abeona is a commercial-stage biopharmaceutical company focused on cell and gene therapies for serious diseases, including its marketed product ZEVASKYN for RDEB.
• 2mo ago AI analysis › Press Release
Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®
Abeona Therapeutics announced the activation of Cincinnati Children’s as the seventh Qualified Treatment Center for ZEVASKYN, its gene therapy for RDEB.
Cincinnati Children’s is noted as one of the largest Epidermolysis Bullosa centers in the US, a move that significantly broadens patient access to the first and only autologous cell sheet-based gene therapy for this condition.
The company continues to expand its commercial footprint through the Abeona Assist program to support patient navigation and logistics.
• 3mo ago AI analysis › Press Release
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics granted inducement equity awards to five new non-executive employees, approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The awards cover an aggregate of 9,000 restricted shares of common stock granted on June 30, 2026.
The shares are scheduled to vest in three equal annual installments on each anniversary of the grant date, subject to continued employment.
• 4mo ago AI analysis › Press Release
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • 5mo ago Press Release
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
Abeona Therapeutics announced that management will participate in two major healthcare investor conferences in June 2026.
The company will hold a fireside chat at the Jefferies Global Healthcare Conference on June 4 and investor meetings at the Goldman Sachs Global Healthcare Conference on June 8.
A live webcast of the Jefferies fireside chat will be available on the company's investor relations website.
• 5mo ago AI analysis › Press Release ● Major
Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update
globenewswire.com • 5mo ago Press Release
Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®
globenewswire.com • 5mo ago Press Release
Abeona Therapeutics® Announces Date of First Quarter Financial Results
Abeona Therapeutics announced it will hold a conference call on May 13, 2026, to discuss first quarter financial results and corporate progress.
The call is scheduled for 8:30 a.m. ET and will be accessible via webcast and teleconference, with a replay available for 30 days.
The company is a commercial-stage biopharmaceutical firm focused on cell and gene therapies, specifically its lead product ZEVASKYN for RDEB.
• 5mo ago AI analysis › Press Release
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics granted restricted stock awards to eight new non-executive employees, totaling 112,621 shares, under Nasdaq Listing Rule 5635(c)(4).
The awards vest in equal annual installments over three years, subject to continued employment with the company.
Abeona remains focused on its commercial-stage cell and gene therapy portfolio, including its lead product ZEVASKYN for RDEB.
• 6mo ago AI analysis › Press Release ● Major
Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors
globenewswire.com • 6mo ago Press Release
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York
globenewswire.com • 6mo ago 
